

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 June 2021 (17.06.2021)



(10) International Publication Number
WO 2021/116874 A1

(51) International Patent Classification:

C07C 215/12 (2006.01) C07D 405/14 (2006.01)
A61P 3/00 (2006.01) A61K 31/4545 (2006.01)
A61P 5/00 (2006.01) A61P 25/00 (2006.01)

(21) International Application Number:

PCT/IB2020/061585

(22) International Filing Date:

07 December 2020 (07.12.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/946,084 10 December 2019 (10.12.2019) US

(71) Applicant: **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, New York 10017 (US).

(72) Inventors: **ASPINES, Gary E.**; c/o Pfizer Inc., 445 Eastern Point Road, Bldg. 98, Groton, Connecticut 06340 (US). **BAGLEY, Scott W.**; c/o Pfizer Inc., 445 Eastern Point Road, Bldg. 98, Groton, Connecticut 06340 (US). **CLARK, Wesley Dewitt**; c/o Pfizer Inc., 445 Eastern Point Road, Bldg. 98, Groton, Connecticut 06340 (US). **CURTO, John M.**; c/o Pfizer Inc., 445 Eastern Point Road, Bldg. 98, Groton, Connecticut 06340 (US). **EDMONDS, David James**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **FLANAGAN, Mark E.**; c/o Pfizer Inc., 445 Eastern Point Road, Bldg. 98, Groton, Connecticut 06340 (US). **FUTATSUGI, Kentaro**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **GRIFFITH, David Andrew**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **HUARD, Kim**; 2139 Spaulding Avenue, Berkeley, California 94703 (US). **LIAN, Yajing**; c/o Pfizer Inc., 445 Eastern Point Road, Bldg. 98, Groton, Connecticut 06340 (US). **LIMBERAKIS, Chris**; c/o Pfizer Inc., 445 Eastern Point Road, Bldg. 98, Groton, Connecticut 06340 (US). **LONDREGAN, Allyn T.**; c/o Pfizer Inc., 445 Eastern Point Road, Bldg. 98, Groton, Connecticut 06340 (US). **MATH-IOWETZ, Alan M.**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **PIOTROWSKI, David Walter**; c/o Pfizer Inc., 445 Eastern Point Road, Bldg. 98, Groton, Connecticut 06340 (US). **RUGGERI, Roger B.**; 53 Twin Lakes Drive, Waterford, Connecticut 06385 (US).

(74) Agent: **ZIELINSKI, Bryan C.**; PFIZER INC., 235 East 42nd Street, MS 235/9/86, New York, New York 10017 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: SOLID FORMS OF 2-((4-((S)-2-(5-CHLOROPYRIDIN-2-YL)-2-METHYLBENZO[D] [1,3]DIOXOL-4-YL)PIPERIDIN-1-YL)METHYL)-1-((S)-OXETAN-2-YL)METHYL)-1H-BENZO[D] IMIDAZOLE-6-CARBOXYLIC ACID, 1,3-DIHYDROXY-2-(HYDROXYMETHYL)PROPAN-2-AMINE SALT

(57) Abstract: The invention provides solid forms of 2-((4-((S)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt for example, a hydrate (e.g. a monohydrate) crystalline form (e.g. Form 2 or Form 3) or an amorphous form; as well as pharmaceutical compositions, and the uses thereof in treating diseases, conditions or disorders modulated by GLP-1R in a mammal, such as a human.



WO 2021/116874 A1